SML3682

ST2825

≥98% (HPLC)

• Synonym(e): (2R,4′R,8′aR)-1-[2-[4-[[2-(2,4-Dichlorophenoxy)acetyl]amino]phenyl]acetyl]tetrahydro-6′-oxo-spiro[pyrrolidine-2,7′(6′H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4′-carboxamide, PAM4-SP19-Beta8-NH2, ST 2825, ST-2825
• Empirische Formel (Hill-System): C₂₇H₂₈Cl₂N₄O₅S
• CAS-Nummer: 894787-30-5
• Molekulargewicht: 591.51
• MDL-Nummer: MFCD30207830
• UNSPSC-Code: 51111800
• UNSPSC-Code: 12352200
• NACRES: NA.21

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 2 mg/mL, clear
• Lagertemp.: -10 to -25°C

Beschreibung

Biochem./physiol. Wirkung

ST2825 is an orally active peptidomimetic of a heptapeptide structure in the MyD88 TIR BB-loop. ST2825 prevents IL-1beta-mediated activation of NF-kappaB by blocking MyD88 homodimerization and thereby the recruitment of IL-1 receptor-associated kinases IRAK1/4. ST2825 at 10 µg/mL completely suppresses 2.5 µg/mL TLR9 ligand ODN 2006-induced B-cell plasma cell differentation and antibodies production from PBMCs. ST2825 inhibits IL-1β-induced IL-6 production in mice (100 & 200 mg/kg p.o. prior to 20 µg/kg IL-1β i.p.) and protects against left ventricular (LV) dilatation and hypertrophy (25 mg/kg/day i.p.) in a murine model of nonreperfused acute myocardial infarction (AMI) in vivo.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable